DISCOVERYNCT07390643
The DISCOVER Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 4 words Show 6 more changesShow less
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Primary completion date changed from estimate of Jan 31, 2027 to Sep 24, 2026
- Study completion pushed from Jan 31, 2028 to Oct 31, 2028
- Start date changed from estimate of Jul 2026 to Feb 11, 2026
- Secondary endpoints: details revised at 1 of 5 entries
- Site contact updated
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (5)
Arms and interventions
Enrolled participants will complete: * Baseline visit with blood draw and questionnaires * Return of test results: * For a positive result, diagnostic work-up could include clinic visits, biopsy, surgery, imaging assessments such as ultrasound, Computed Tomography (CT) scans, or Magnetic Resonance Imaging (MRI) scans. If standard, diagnostic work-up is positive or negative for cancer, follow up will be at the discretion of the principal investigator. * For a negative MCED blood test with standard, diagnostic work-up that is negative, follow-up will be at the discretion of the principal investigator. * Online post-test questionnaire * Online post-diagnostic questionnaire * Follow up will be up to 24 months
Devices: GRAIL Galleri MCED test
Sites
1 site in 1 country
- Dana-Farber Cancer InstituteBoston, Massachusetts, United States